Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Q4 2024 Solesence Earnings Call

In This Article:

Participants

Jess Jankowski; President, Chief Executive Officer, Chief Financial Officer, Director; Solesence Inc

Kevin Cureton; Chief Operating Officer; Solesence Inc

Tony Reuben

Wayne Ruan

Ronald Richards

James Bennett Liberman; Analyst; American Trust Investment Services, Inc.

John Henderson; Analyst; Inflections Consulting

Stefano Bolis

Presentation

Operator

Good day. Thank you for standing by. Welcome to the Solesence fourth quarter 2024 conference call. (Operator Instructions) Today's call is being recorded.
During this call, management will make statements that include forward-looking statements within the meaning of the federal securities laws, which are pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. This conference call may contain statements that reflect the company's current beliefs and a number of important factors could cause actual results for future periods to differ materially from those stated on this call. These important factors include, without limitation, a decision of the customer to cancel purchase order or supplies agreement, demand for and acceptance of the company's personal care ingredients, advanced materials and formulated products, changes in development and distribution relationships, the impact of competitive products and technology, possible disruption in commercial activities occasioned by public health issues, terrorist activity and armed conflict and other risks indicated in the company's filings with the Securities and Exchange Commission.
Except as required by federal securities laws, the company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties or other contingencies.
I will now hand the conference over to your speaker, Mr. Jess Jankowski, President, CEO and CFO.

Jess Jankowski

Thank you, operator. Good morning, and thanks to all of you who have joined our call today.
Joining me on today's call is Kevin Cureton, our Chief Operating Officer.
I'll begin with a summary of our fourth quarter results and a business update. Kevin will then discuss our operational initiatives. Then we will take your questions.
We're excited to be hosting our first conference call as Solesence, reflecting our simple yet profound mission: deliver joy. We believe that joy comes from confidence, self-expression and well-being, and we're committed to enhancing all lives by transforming skin care through our groundbreaking innovations.
Our rebranding also reinforces the broad success of our beauty science platform, which is not only revolutionized mineral-based sun and environmental protection, but it has also enabled us to achieve four consecutive years of growth. With more beauty brands recognizing the novel skin health benefits that our platform brings, we remain confident in our ability to sustain rapid and profitable expansion in the years ahead.
In connection with our rebrand, we launched a new Investor Relations website, enabling current and prospective investors to stay better informed of our developments. Our new IR site offers comprehensive information about the company, including detailed financial reports, historic Nanophase financials and disclosures, leadership team and Board of Director profiles, the company's news and announcements and much more. We invite our investors to view our site.
Moving to our financial results. We had an impressive 2024, achieving record net profit and positive operating cash flow, while reducing our outstanding debt. These milestones highlighted the continued success of our growth strategy underscored by the ingenuity and creativity of our team as we continued to promote our award-winning products.
Revenue for the fourth quarter reached $12.6 million, representing an increase of 57% year-over-year. For the full year, we generated $52.3 million in revenue, an increase of more than 40%, exceeding our base guidance expectations.
These record results reflect the continued strength of our commercial execution and the continued demand for our products. The elevated fourth quarter revenue was primarily driven by a shift in customer mix and the timing of product launches, many of which occurred later in the year than in previous cycles.
We're pleased to be growing at a robust pace and thrilled to be doing this while expanding our margins. Gross margin expanded to 22% from 6% year-over-year in the fourth quarter. On a full year basis, our success was more evident as we increased our gross margin to 31% from 21% year-over-year. I'd like to remind listeners that the fourth quarter has typically been our seasonally weakest, but in spite of these usual fluctuations, our business continues to yield positive results.
Our fourth quarter 2024 net loss was narrowed to $600,000 from a $2.1 million net loss in the prior year period. For the full year we generated net income of $4.2 million, a sharp increase from a net loss of $4.4 million in 2023, representing an $8.6 million improvement year-over-year.
Our business model and products underscore the success that we're able to achieve. Customers recognize the value of our products, and that speaks to the quality that we deliver. We continue to execute well, growing relationships with a series of leading brand partners across our line of consumer products. These include Colorescience, a leading dermatologist recommended brand; Tatcha, a Japanese inspired Prestige brand; and Credo, the leading clean beauty retailer. There are a series of other brand partners who are not at liberty to disclose, but represent a large percentage of our revenue mix.
Our strong financial results were achieved in part because we have an amazing product at just won another award. Au Lait Face Milk SPF 50+ featuring Solesence Kleair technology was named a winner in the Best Prestige Finished Formula category at the 2025 Cosmetics & Toiletries C&T Alle Awards. This award recognizes the company's achievements across criteria, including novelty and practicality, sustainability, safety, stability and proof of efficacy. It also marks the company's third consecutive win at the prestigious Alle Awards. Listeners may recall that in 2024, in addition to an Alle Award, we also won our third consecutive Cosmopack award for best formulation at Cosmoprof, North America.
Shifting gears, another customer that recognizes the quality and performance inherent in the personal care ingredients we supply is BASF, one of our largest customers in 2024. We have a long-term exclusive relationship with BASF primarily to provide nanoscale specific sync oxide-based active pharmaceutical ingredients, or APIs, in personal care cosmetics with sunscreens and daily wear products being the dominant applications.
We expect that these successful relationships as well as future customer demand will contribute to our future growth.
Looking ahead to 2025, we anticipate sustaining momentum both on the top and bottom lines. We expect to generate continued growth supported by solid demand from brand partners and customers who remain enthusiastic about the unique benefits and performance that our products bring to enhance end consumers' health and well-being. We remain on track to deliver additional volume in 2025 as demand for our products outpaces the current market growth rate while continuing to enhance our operational efficiencies and scale for growth.
At this time, I'll turn the call to Kevin Cureton, our Chief Operating Officer, to share an update of our progress and outlook. Kevin?